Sherry Aulin - 18 Dec 2024 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Chief Financial Officer
Signature
/s/ Nathaniel Adams, Attorney-in-fact
Issuer symbol
XENE
Transactions as of
18 Dec 2024
Net transactions value
-$770,999
Form type
4
Filing time
19 Dec 2024, 18:57:42 UTC
Previous filing
12 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XENE Common Shares Options Exercise $88,113 +9,334 $9.44 9,334 18 Dec 2024 Direct
transaction XENE Common Shares Tax liability $88,133 -2,135 -23% $41.28 7,199 18 Dec 2024 Direct F1
transaction XENE Common Shares Sale $296,815 -7,199 -100% $41.23 0 18 Dec 2024 Direct
transaction XENE Common Shares Options Exercise $185,280 +16,000 $11.58 16,000 18 Dec 2024 Direct
transaction XENE Common Shares Tax liability $185,347 -4,490 -28% $41.28 11,510 18 Dec 2024 Direct F1
transaction XENE Common Shares Sale $474,097 -11,510 -100% $41.19 0 18 Dec 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -9,334 -100% $0.000000 0 18 Dec 2024 Common Shares 9,334 $9.44 Direct F3
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -16,000 -73% $0.000000 6,000 18 Dec 2024 Common Shares 16,000 $11.58 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the closing price of the Company's common shares on December 17, 2024 for purposes of net settlement calculations.
F2 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.19 to $41.20, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 The shares subject to the option are fully vested and exercisable.